GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.
PMID:22047130
| Citation |
Virgili, N, Espinosa-Parrilla, JF, Mancera, P, Pastén-Zamorano, A, Gimeno-Bayon, J, Rodríguez, MJ, Mahy, N and Pugliese, M (2011) Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis. J Neuroinflammation 8:149 |
|---|---|
| Abstract |
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disorder of the central nervous system (CNS) and is the leading cause of nontraumatic disability among young adults. Activated microglial cells are important effectors of demyelination and neurodegeneration, by secreting cytokines and others neurotoxic agents. Previous studies have demonstrated that microglia expresses ATP-sensitive potassium (KATP) channels and its pharmacological activation can provide neuroprotective and anti-inflammatory effects. In this study, we have examined the effect of oral administration of KATP channel opener diazoxide on induced experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. |
| Links |
PubMed PMC3215935 Online version:10.1186/1742-2094-8-149 |
| Keywords |
Administration, Oral; Animals; Anti-Inflammatory Agents/administration & dosage; Anti-Inflammatory Agents/pharmacology; Anti-Inflammatory Agents/therapeutic use; Antihypertensive Agents/administration & dosage; Antihypertensive Agents/pharmacology; Cell Line; Diazoxide/administration & dosage; Diazoxide/pharmacology; Diazoxide/therapeutic use; Disease Models, Animal; Disease Progression; Encephalomyelitis, Autoimmune, Experimental/drug therapy; Encephalomyelitis, Autoimmune, Experimental/physiopathology; Female; Humans; Interferon-gamma/pharmacology; Interleukin-6/immunology; KATP Channels/metabolism; Lipopolysaccharides/pharmacology; Mice; Mice, Inbred C57BL; Microglia/cytology; Microglia/drug effects; Microglia/immunology; Multiple Sclerosis/drug therapy; Multiple Sclerosis/physiopathology; Nitrites/metabolism; Tumor Necrosis Factor-alpha/immunology |
| edit table |
Significance
Annotations
| Gene product | Qualifier | GO Term | Evidence Code | with/from | Aspect | Extension | Notes | Status |
|---|---|---|---|---|---|---|---|---|
| GO:0042493: response to drug |
ECO:0000314: |
P |
Figure 2C treatment with diazoxide decreases release of IL-6 in a dose dependent manner |
complete | ||||
See also
References
See Help:References for how to manage references in GONUTS.
